05.14.25 -- Challenges In Manufacturing TIL For Clinical Trials

Vial fogging is a common phenomenon observed in lyophilized biologic drug products. Examine two case studies that explore critical factors contributing to vial fogging and inform vial selection decisions.

Discover the advantages of a filling technology that provides faster readiness to good manufacturing practices (GMP) filling compared with traditional options.

Pre-use, post-sterilization integrity testing (PUPSIT) ensures filters remain undamaged and effective during aseptic manufacturing. Discover how you can successfully perform PUPSIT with proven solutions.

Watch to explore two novel approaches that have been developed to overcome the limitation of a filter's viral retention performance in continuous processes.

The complex biology of rare diseases creates unique hurdles, making it difficult to design and implement a drug development program. Explore the unique considerations for drug product manufacturing.

As the demand for oligonucleotides (oligos) increases in research, therapeutics, and drug development, so does the need for advanced technologies to enhance oligo manufacturing workflows.

Enhance the quality and safety of your BsAb therapeutics with a highly efficient with the right chromatography hydroxyapatite media.

Size homogeneity of a mAb in solution is crucial for comparability and characterization. Here, an IgG1 antibody was cleaved into antigen-binding fragments via pepsin and papain digestion, then purified.

Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.